Cyteir Therapeutics, Inc. Common Stock
CYT
CYT was delisted on the 15th of March, 2024.
45 hedge funds and large institutions have $56.8M invested in Cyteir Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 8 increasing their positions, 15 reducing their positions, and 19 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less funds holding
Funds holding: 52 → 45 (-7)
26% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 19
32% less capital invested
Capital invested by funds: $83.8M → $56.8M (-$27M)
47% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$4.68M |
| 2 |
NM
Newtyn Management
New York
|
+$1.55M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$918K |
| 4 |
Renaissance Technologies
New York
|
+$637K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$579K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$12.6M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$6.49M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.61M |
| 4 |
BlackRock
New York
|
-$1.18M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$380K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Wells Fargo
San Francisco,
California
| – | -$8.97K | -3,511 | -99% |
|
52
Barclays
London,
United Kingdom
| – | -$7.49K | -2,934 | -97% |
|
53
Allspring Global Investments
Charlotte,
North Carolina
| – | -$10K | -2,868 | Closed |
|
54
Legal & General Group
London,
United Kingdom
| – | -$8K | -2,122 | Closed |
|
|
SO
55
STRS Ohio
Columbus,
Ohio
| – | -$7K | -1,900 | Closed |
|
|
AB
56
Amalgamated Bank
New York
| – | -$5K | -1,232 | Closed |
|
57
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$4K | -1,147 | Closed |
|
|
AIP
58
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$2K | -641 | Closed |
|
|
PHK
59
Point72 Hong Kong
Hong Kong
| – | -$1K | -231 | Closed |
|
|
LC
60
Lindbrook Capital
Calabasas,
California
| – | +$15 | +6 | New |
|
|
CS
61
Credit Suisse
Zurich,
Switzerland
| – | +$26 | +10 | New |
|
|
EI
62
Ellevest Inc
New York
| – | +$125 | +49 | New |
|
CYT Hedge Fund Activity: Q2 2022 in Review
45 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Cyteir Therapeutics, Inc. Common Stock (CYT) for Q2 2022, worth a combined $56.8M — down 32% from $83.8M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of CYT and 14 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 8 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $4.68M. The largest seller was RA Capital Management, exiting entirely with an estimated $12.6M sold.
- 45 institutional investors held Cyteir Therapeutics, Inc. Common Stock (CYT) as of Q2 2022, down from 52 in Q1 2022.
- Funds reported $56.8M of Cyteir Therapeutics, Inc. Common Stock stock for Q2 2022, down 32% quarter-over-quarter.
- 14 funds opened new Cyteir Therapeutics, Inc. Common Stock positions in Q2 2022 and 19 closed out, a net change of -5 holders.
- The largest Cyteir Therapeutics, Inc. Common Stock buyer in Q2 2022 was Baker Bros. Advisors, an estimated $4.68M added.
- The largest Cyteir Therapeutics, Inc. Common Stock seller in Q2 2022 was RA Capital Management, an estimated $12.6M sold.
Based on aggregated 13F filings for Q2 2022.